Non-small cell lung cancer stage IIIB

• A randomized phase II study of Pembrolizumab (MK-3475) as maintainance therapy in patients with unresectable stage III non-small cell lung … Pending
  2024-514701-57-01 4 "non Small Cell Lung Cancer"
• A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacitu … Pending
  2024-517561-16-00 4 "non-small cell lung cancer"
• An Open-label, Multicenter, Phase 1a/1b Study to Evaluate the Safety and Anti-tumor Activity of TT125-802 in Combination With Adagrasib, Osi … Pending
  2024-519071-25-00 3 "Advanced NSCLC"
• Trial assessing treatment in patients with advanced Lung Cancer and Interstitial Lung Disease Pending
  2025-522790-10-00 4 "Non Small Cell Lung Cancer"
• A Study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-po … Recruiting
  2023-505604-32-00 5 2024-01-24 "Non small cell lung cancer (NSCLC)"
• A clinical study to investigate the efficacy and safety of an investigational combination therapy with BNT324 and BNT327 in patients with ad … Recruiting
  2024-520238-31-01 9 2026-04-20 "Advanced Lung Cancer"
• A clinical trial to test if an investigational combination therapy with BNT326 and BNT327 is safe and potentially beneficial for people with … Recruiting
  2024-519344-32-00 9 2026-03-16 "Non-small Cell Lung Cancer"
• Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting
  2024-515764-31-00 10 2025-06-13 "Non-small cell lung cancer"
• A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lun … Recruiting
  2023-506539-14-00 3 2025-05-27 "Oncology"
• A study to evaluate the benefit of adding durvalumab after chemotherapy, durvalumab and surgery in patients with early-stage, operable, non- … Recruiting
  2023-508773-82-00 5 2025-05-06 "Stage IIB-IIIB (N2) resectable non small cell lung cancer"
• Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in … Recruiting
  2024-514465-18-00 9 2025-04-23 "Advanced or Metastatic Non-Squamous NSCLC"
• Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting
  2023-508012-35-00 5 2024-10-02 "Newly diagnosed NSCLC with resectable clinical Stage II, III"
• Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting
  2023-508852-21-00 4 2022-06-10 "Resectable, Early-stage (II to IIIB) Non-small Cell Lung Can"
• IFCT-2201 ADAPTABLE A study evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced lung cancer progre … Recruitment ended
  2022-502103-30-00 4 2023-04-25 "advanced non-squamous non-small cell lung cancer"
• IFCT-2101 MASTERPROTOCOL ALK : Study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monot … Recruitment ended
  2023-510387-13-00 4 2022-05-18 "advanced ALK-positive non-small cell lung cancer"
• Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) Recruitment ended
  2024-512028-12-00 4 2021-03-19 "Advanced ROS1-positive non-small cell lung cancer"
• Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors Recruitment ended
  2023-503812-34-00 4 2019-02-13 "Locally Advanced or Metastatic Disease in Solid Tumors"
• eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Recruitment ended
  2024-513454-29-00 5 2015-10-15 "Non-Small Cell Lung Cancer (NSCLC)"
• A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE Ended
  2022-502716-37-00 4 2023-11-27 "Recurrent or advanced/metastatic solid tumors who are immuno"
• A clinical study to test the safety and efficacy of GB1211 in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSC … Ended
  2024-514419-93-00 9 2022-05-19 "Study to investigate the safety and efficacy of GB1211 (a ga"
• A first-in-human clinical trial in adult patients with advanced non-small cell lung cancer of a personalised therapy targeting specific muta … Ended
  2024-513060-26-00 7 2021-04-07 "Non-small cell lung cancer"
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit … Ended
  2023-508443-40-00 5 2020-12-18 "Lung Cancer, Non-Small Cell"
• Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy - Employing optimized (hypofra … Ended
  2024-513948-28-00 4 2020-05-08 "unresectable stage III NSCLC (Non–small-cell lung cancer)"
• A clinical trial to evaluate if CC-486 plus pembrolizumab works and is safe in patients with advanced or metastatic non-small cell lung canc … Ended
  2024-513405-31-00 4 2015-12-10 "Second-line treatment of locally advanced or metastatic non-"

Showing 1–24 of 24 trials